Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 1:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 12,573 matching trials from the live ClinicalTrials.gov search.
Conditions
Hailey Hailey Disease, Skin Diseases, Lesion Skin
Interventions
KB111
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Completed Not applicable Interventional Results available

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

NCT01232946
Conditions
Type 2 Diabetes
Interventions
liraglutide, insulin detemir, liraglutide plus insulin detemir
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Active, not recruiting Not applicable Interventional

Combination Therapy to Improve SCI Recovery.

NCT05563103
Conditions
Spinal Cord Injuries
Interventions
Daily acute intermittent hypoxia, Room air (SHAM), Walking + tSTIM, Walking + Sham transcutaneous spinal stimulation (tSHAM)
Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Cambridge, Massachusetts
Conditions
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A, Imaging Technique
Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Diabetes Mellitus, Type 2
Interventions
Lispro Mixture Therapy, Glargine Basal-Bolus Therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
44
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 41 more
Conditions
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Interventions
Decitabine/cedazuridine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Abexinostat, Pembrolizumab
Drug · Biological
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, ifosfamide, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Plaque Psoriasis
Interventions
Calcipotriene/betamethasone
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Glioblastoma
Interventions
BKM120 + temozolomide, BKM120 +temozolomide with/without radiotherapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Fayetteville, Arkansas • Boston, Massachusetts • Houston, Texas
Conditions
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Mesothelioma, Esophageal Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Salivary Gland Carcinomas, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Throat, Small Cell Lung Cancer ( SCLC ), Lung Cancer (Locally Advanced or Metastatic), Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea
Interventions
VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
Drug
Lead sponsor
VM Oncology, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
12
States / cities
Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 9 more
Conditions
Acute Graft-versus-host Disease
Interventions
Itacitinib, Corticosteroids
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
28 Days to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Duarte, California • Orange, California • Aurora, Colorado + 10 more
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, Peginterferon alfa-2b (PEG-Intron), Peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 36 more
Conditions
Cervical Cancer
Interventions
cetuximab, cisplatin
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
18
States / cities
Burbank, California • Los Angeles, California • Savannah, Georgia + 14 more
Conditions
Metastatic Melanoma
Interventions
Vaccination with RNA-transfected mature autologous DC
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
Interventions
Atezolizumab, Bendamustine, Cyclophosphamide, Doxorubicin, Obinutuzumab, Prednisone, Vincristine, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 5 more
Completed Phase 2 Interventional Results available

Dextroamphetamine and tDCS to Improve the Fluency

NCT02514044
Conditions
Stroke
Interventions
Dexedrine, Active tDCS, Speech Therapy, Placebo, Sham tDCS
Drug · Device · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Albuminuria
Interventions
Ramipril + Irbesartan, Ramipril + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
11
States / cities
Tustin, California • Miami, Florida • West Palm Beach, Florida + 8 more
Conditions
Patellofemoral Pain Syndrome
Interventions
transcranial direct current stimulator
Device
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Petosemtamab, Pembrolizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
36
States / cities
Mobile, Alabama • La Jolla, California • Los Angeles, California + 30 more
Conditions
Prostate Cancer
Interventions
Photodynamic Therapy (PDT), Verteporfin Injection
Device · Drug
Lead sponsor
SpectraCure AB
Industry
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more
Conditions
Obesity
Interventions
Phentermine-Topiramate, Meal Replacement Therapy, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
Postoperative chemotherapy, Perioperative chemotherapy
Procedure
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
283
States / cities
Antioch, California • Duarte, California • Fremont, California + 210 more